E-29 | Association of Body Mass Index with Chronic Total Occlusion Percutaneous Coronary Intervention Outcomes: Insights from the Prospective Global Registry for the Study of Chronic Total Occlusion Interventions (PROGRESS-CTO) (2022)

BackgroundThe association between body mass index (BMI) and the outcomes of chronic total occlusion percutaneous coronary intervention (CTO PCI) has received limited study.MethodsWe examined the procedural outcomes of CTO PCIs in Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS-CTO, NCT02061436) stratified by BMI (18.5-≤25, normal; 25-30, overweight; ≥30, obese).ResultsOut of 8,401 patients who underwent CTO PCI at 36 centers between 2012-2022; 1,266 (15%) had normal BMI, 3,026 (36%) were overweight, and 4,109 (49%) were obese. Mean age was 64±10, 82% were men with a high prevalence of comorbidities: hypertension (90%), dyslipidemia (86%), diabetes mellitus (43%). Technical success was significantly lower in patients with obesity compared with those without (84.7% vs 87.4%, p<0.001); however, major adverse cardiovascular events (MACE) were similar among the three BMI groups (2.8%, 1.9%, 1.9%, p=0.085) (Figure). Contrast volume (224±111, 233±121, 232±114, ml, p<0.001) and Air Kerma (AK) fluoroscopy dose (2.0±1.9, 2.5±2.2, 3.2±2.5, Gray, p<0.001) were significantly higher in patients with higher BMI. Fluoroscopy time (50±33, 49±34, 51±33, min, p=0.717) and procedure time (130±77, 127±78, 133±79, min, p=0.318) were similar between the groups (normal weight, overweight, obese, respectively).ConclusionsDisclosuresK. Alaswad: consultant and speaker for Boston Scientific, Abbott Cardiovascular, Teleflex, and CSI: Consulting; D. Karmpaliotis: Abbott: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; Saranas: Ownership Interests: Stocks, Stock Options; Soundbite: Ownership Interests: Stocks, Stock Options; Traverse Vascular: Ownership Interests: Stocks, Stock Options; F. A. Jaffer: sponsored research support from Kowa, Canon, Siemens, Teleflex, Shockwave, and Amarin; consultant for Boston Scientific, Abbott Vascular, Siemens, Magenta Medical, Asahi Intecc and IMDS; has an equity interest in Intravascular Imaging, Inc. and DurVena, I: Consulting; D. Doshi: speaker’s bureau for Abbott Vascular, Boston Scientific, and Medtronic and has research support from Biotronik: Consulting; J. Khatri: Medtronic, Abbott, Boston, Terumo, Asahi speaker/proctor.: Consulting; R. E. Davies: Medtronic: Speaker Bureau; Asahi Intec: Speaker Bureau; Shockwave: Advisory Board/Board Member; Siemens healthineers/Corindus: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; L. Azzalini: Honoraria from Abbott Vascular, Guerbet, Terumo, and Sahajanand Medical Technologies and research support from ACIST Medical Systems, Guerbet, and Terumo.: Consulting; A. Elguindy: Honoraria: Medtronic, Boston Scientific, Asahi Intecc, Abbott Proctorship fees: Medtronic, Boston Scientific, Asahi Intecc, Terumo Educational grants: Medtronic: Consulting; B. Jefferson: honoraria/consulting/speaking fees from Abbott, Boston Scientific, CSI, Medtronic: Consulting; M. P. Patel: Abbott: Consulting; Cardiovascular Systems, Inc.: Consulting; Medtronic: Consulting; E. S. Brilakis: Abbott: Consulting and Speaker Bureau; AMgen: Consulting and Speaker Bureau; Asahi Intecc: Speaker Bureau; Biotronik: Consulting and Speaker Bureau; Boston Scientific Corp.: Consulting, Principal Investigator for a Research Study and Speaker Bureau; ControlRad: Speaker Bureau; CSI: Consulting and Speaker Bureau; GE Healthcare: Consulting, Principal Investigator for a Research Study and Speaker Bureau; Hippocrates LLC: Ownership Interests: Stocks, Stock Options; MHI Ventures: Ownership Interests: Stocks, Stock Options; Cleerly Health: Ownership Interests: Stocks, Stock Options; Stallion Medical: Ownership Interests: Stocks, Stock Options; B. Simsek Nothing to disclose. S. Kostantinis Nothing to disclose. J. Karacsonyi Nothing to disclose. A. Masoumi Nothing to disclose. P. Poommipanit Nothing to disclose. Ş. Görgülü Nothing to disclose. Ö. Göktekin Nothing to disclose. O. Krestyaninov Nothing to disclose. T. N. Patel Nothing to disclose. R. H. Chandwaney Nothing to disclose. O. C. Mastrodemos Nothing to disclose. B. V. Rangan Nothing to disclose. BackgroundThe association between body mass index (BMI) and the outcomes of chronic total occlusion percutaneous coronary intervention (CTO PCI) has received limited study. The association between body mass index (BMI) and the outcomes of chronic total occlusion percutaneous coronary intervention (CTO PCI) has received limited study. MethodsWe examined the procedural outcomes of CTO PCIs in Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS-CTO, NCT02061436) stratified by BMI (18.5-≤25, normal; 25-30, overweight; ≥30, obese). We examined the procedural outcomes of CTO PCIs in Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS-CTO, NCT02061436) stratified by BMI (18.5-≤25, normal; 25-30, overweight; ≥30, obese). ResultsOut of 8,401 patients who underwent CTO PCI at 36 centers between 2012-2022; 1,266 (15%) had normal BMI, 3,026 (36%) were overweight, and 4,109 (49%) were obese. Mean age was 64±10, 82% were men with a high prevalence of comorbidities: hypertension (90%), dyslipidemia (86%), diabetes mellitus (43%). Technical success was significantly lower in patients with obesity compared with those without (84.7% vs 87.4%, p<0.001); however, major adverse cardiovascular events (MACE) were similar among the three BMI groups (2.8%, 1.9%, 1.9%, p=0.085) (Figure). Contrast volume (224±111, 233±121, 232±114, ml, p<0.001) and Air Kerma (AK) fluoroscopy dose (2.0±1.9, 2.5±2.2, 3.2±2.5, Gray, p<0.001) were significantly higher in patients with higher BMI. Fluoroscopy time (50±33, 49±34, 51±33, min, p=0.717) and procedure time (130±77, 127±78, 133±79, min, p=0.318) were similar between the groups (normal weight, overweight, obese, respectively). Out of 8,401 patients who underwent CTO PCI at 36 centers between 2012-2022; 1,266 (15%) had normal BMI, 3,026 (36%) were overweight, and 4,109 (49%) were obese. Mean age was 64±10, 82% were men with a high prevalence of comorbidities: hypertension (90%), dyslipidemia (86%), diabetes mellitus (43%). Technical success was significantly lower in patients with obesity compared with those without (84.7% vs 87.4%, p<0.001); however, major adverse cardiovascular events (MACE) were similar among the three BMI groups (2.8%, 1.9%, 1.9%, p=0.085) (Figure). Contrast volume (224±111, 233±121, 232±114, ml, p<0.001) and Air Kerma (AK) fluoroscopy dose (2.0±1.9, 2.5±2.2, 3.2±2.5, Gray, p<0.001) were significantly higher in patients with higher BMI. Fluoroscopy time (50±33, 49±34, 51±33, min, p=0.717) and procedure time (130±77, 127±78, 133±79, min, p=0.318) were similar between the groups (normal weight, overweight, obese, respectively). Conclusions DisclosuresK. Alaswad: consultant and speaker for Boston Scientific, Abbott Cardiovascular, Teleflex, and CSI: Consulting; D. Karmpaliotis: Abbott: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; Saranas: Ownership Interests: Stocks, Stock Options; Soundbite: Ownership Interests: Stocks, Stock Options; Traverse Vascular: Ownership Interests: Stocks, Stock Options; F. A. Jaffer: sponsored research support from Kowa, Canon, Siemens, Teleflex, Shockwave, and Amarin; consultant for Boston Scientific, Abbott Vascular, Siemens, Magenta Medical, Asahi Intecc and IMDS; has an equity interest in Intravascular Imaging, Inc. and DurVena, I: Consulting; D. Doshi: speaker’s bureau for Abbott Vascular, Boston Scientific, and Medtronic and has research support from Biotronik: Consulting; J. Khatri: Medtronic, Abbott, Boston, Terumo, Asahi speaker/proctor.: Consulting; R. E. Davies: Medtronic: Speaker Bureau; Asahi Intec: Speaker Bureau; Shockwave: Advisory Board/Board Member; Siemens healthineers/Corindus: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; L. Azzalini: Honoraria from Abbott Vascular, Guerbet, Terumo, and Sahajanand Medical Technologies and research support from ACIST Medical Systems, Guerbet, and Terumo.: Consulting; A. Elguindy: Honoraria: Medtronic, Boston Scientific, Asahi Intecc, Abbott Proctorship fees: Medtronic, Boston Scientific, Asahi Intecc, Terumo Educational grants: Medtronic: Consulting; B. Jefferson: honoraria/consulting/speaking fees from Abbott, Boston Scientific, CSI, Medtronic: Consulting; M. P. Patel: Abbott: Consulting; Cardiovascular Systems, Inc.: Consulting; Medtronic: Consulting; E. S. Brilakis: Abbott: Consulting and Speaker Bureau; AMgen: Consulting and Speaker Bureau; Asahi Intecc: Speaker Bureau; Biotronik: Consulting and Speaker Bureau; Boston Scientific Corp.: Consulting, Principal Investigator for a Research Study and Speaker Bureau; ControlRad: Speaker Bureau; CSI: Consulting and Speaker Bureau; GE Healthcare: Consulting, Principal Investigator for a Research Study and Speaker Bureau; Hippocrates LLC: Ownership Interests: Stocks, Stock Options; MHI Ventures: Ownership Interests: Stocks, Stock Options; Cleerly Health: Ownership Interests: Stocks, Stock Options; Stallion Medical: Ownership Interests: Stocks, Stock Options; B. Simsek Nothing to disclose. S. Kostantinis Nothing to disclose. J. Karacsonyi Nothing to disclose. A. Masoumi Nothing to disclose. P. Poommipanit Nothing to disclose. Ş. Görgülü Nothing to disclose. Ö. Göktekin Nothing to disclose. O. Krestyaninov Nothing to disclose. T. N. Patel Nothing to disclose. R. H. Chandwaney Nothing to disclose. O. C. Mastrodemos Nothing to disclose. B. V. Rangan Nothing to disclose. K. Alaswad: consultant and speaker for Boston Scientific, Abbott Cardiovascular, Teleflex, and CSI: Consulting; D. Karmpaliotis: Abbott: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; Saranas: Ownership Interests: Stocks, Stock Options; Soundbite: Ownership Interests: Stocks, Stock Options; Traverse Vascular: Ownership Interests: Stocks, Stock Options; F. A. Jaffer: sponsored research support from Kowa, Canon, Siemens, Teleflex, Shockwave, and Amarin; consultant for Boston Scientific, Abbott Vascular, Siemens, Magenta Medical, Asahi Intecc and IMDS; has an equity interest in Intravascular Imaging, Inc. and DurVena, I: Consulting; D. Doshi: speaker’s bureau for Abbott Vascular, Boston Scientific, and Medtronic and has research support from Biotronik: Consulting; J. Khatri: Medtronic, Abbott, Boston, Terumo, Asahi speaker/proctor.: Consulting; R. E. Davies: Medtronic: Speaker Bureau; Asahi Intec: Speaker Bureau; Shockwave: Advisory Board/Board Member; Siemens healthineers/Corindus: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; L. Azzalini: Honoraria from Abbott Vascular, Guerbet, Terumo, and Sahajanand Medical Technologies and research support from ACIST Medical Systems, Guerbet, and Terumo.: Consulting; A. Elguindy: Honoraria: Medtronic, Boston Scientific, Asahi Intecc, Abbott Proctorship fees: Medtronic, Boston Scientific, Asahi Intecc, Terumo Educational grants: Medtronic: Consulting; B. Jefferson: honoraria/consulting/speaking fees from Abbott, Boston Scientific, CSI, Medtronic: Consulting; M. P. Patel: Abbott: Consulting; Cardiovascular Systems, Inc.: Consulting; Medtronic: Consulting; E. S. Brilakis: Abbott: Consulting and Speaker Bureau; AMgen: Consulting and Speaker Bureau; Asahi Intecc: Speaker Bureau; Biotronik: Consulting and Speaker Bureau; Boston Scientific Corp.: Consulting, Principal Investigator for a Research Study and Speaker Bureau; ControlRad: Speaker Bureau; CSI: Consulting and Speaker Bureau; GE Healthcare: Consulting, Principal Investigator for a Research Study and Speaker Bureau; Hippocrates LLC: Ownership Interests: Stocks, Stock Options; MHI Ventures: Ownership Interests: Stocks, Stock Options; Cleerly Health: Ownership Interests: Stocks, Stock Options; Stallion Medical: Ownership Interests: Stocks, Stock Options; B. Simsek Nothing to disclose. S. Kostantinis Nothing to disclose. J. Karacsonyi Nothing to disclose. A. Masoumi Nothing to disclose. P. Poommipanit Nothing to disclose. Ş. Görgülü Nothing to disclose. Ö. Göktekin Nothing to disclose. O. Krestyaninov Nothing to disclose. T. N. Patel Nothing to disclose. R. H. Chandwaney Nothing to disclose. O. C. Mastrodemos Nothing to disclose. B. V. Rangan Nothing to disclose.